UiPath (NYSE:PATH) Trading 2.3% Higher

UiPath Inc. (NYSE:PATH - Get Free Report)'s share price traded up 2.3% during trading on Monday . The company traded as high as $21.85 and last traded at $21.70. 2,004,906 shares were traded during mid-day trading, a decline of 78% from the average session volume of 9,217,937 shares. The stock had previously closed at $21.21.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Morgan Stanley increased their price target on UiPath from $17.00 to $25.00 and gave the company an "equal weight" rating in a research note on Thursday, March 14th. Canaccord Genuity Group raised their price objective on UiPath from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, March 15th. Wells Fargo & Company raised their price objective on UiPath from $24.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 14th. Evercore ISI raised their price objective on UiPath from $24.00 to $27.00 and gave the stock an "in-line" rating in a research note on Thursday, March 14th. Finally, Bank of America raised their price objective on UiPath from $26.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 14th. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, UiPath currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.41.

UiPath Price Performance

The firm has a fifty day simple moving average of $23.46 and a 200 day simple moving average of $21.29. The company has a market capitalization of $12.32 billion, a price-to-earnings ratio of -127.37 and a beta of 0.96.

UiPath (NYSE:PATH - Get Free Report) last issued its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. Research analysts predict that UiPath Inc. will post -0.04 EPS for the current year.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the sale, the chief financial officer now directly owns 87,505 shares of the company's stock, valued at $1,998,614.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 31.03% of the company's stock.

Hedge Funds Weigh In On UiPath

Institutional investors have recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC purchased a new position in UiPath during the fourth quarter worth approximately $25,000. HighMark Wealth Management LLC purchased a new stake in shares of UiPath in the 4th quarter valued at $27,000. Tyler Stone Wealth Management acquired a new position in UiPath during the 2nd quarter worth $28,000. Cypress Capital Management LLC WY acquired a new position in UiPath during the 4th quarter worth $29,000. Finally, Fifth Third Bancorp grew its stake in UiPath by 2,005.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company's stock worth $34,000 after purchasing an additional 1,905 shares in the last quarter. Hedge funds and other institutional investors own 62.50% of the company's stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.